These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 24764659

  • 1. Role of cetuximab in first-line treatment of metastatic colorectal cancer.
    Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Díaz-Rubio E.
    World J Gastroenterol; 2014 Apr 21; 20(15):4208-19. PubMed ID: 24764659
    [Abstract] [Full Text] [Related]

  • 2. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
    García-Foncillas J, Díaz-Rubio E.
    Clin Transl Oncol; 2010 Aug 21; 12(8):533-42. PubMed ID: 20709651
    [Abstract] [Full Text] [Related]

  • 3. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.
    Ann Surg; 2010 Feb 21; 251(2):254-60. PubMed ID: 20010090
    [Abstract] [Full Text] [Related]

  • 4. Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA.
    Lyseng-Williamson KA.
    Mol Diagn Ther; 2012 Oct 21; 16(5):317-22. PubMed ID: 23055389
    [Abstract] [Full Text] [Related]

  • 5. Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.
    Feng QY, Wei Y, Chen JW, Chang WJ, Ye LC, Zhu DX, Xu JM.
    World J Gastroenterol; 2014 Apr 21; 20(15):4263-75. PubMed ID: 24764664
    [Abstract] [Full Text] [Related]

  • 6. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
    Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F.
    J Clin Oncol; 2011 May 20; 29(15):2011-9. PubMed ID: 21502544
    [Abstract] [Full Text] [Related]

  • 7. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH.
    Lancet Oncol; 2010 Jan 20; 11(1):38-47. PubMed ID: 19942479
    [Abstract] [Full Text] [Related]

  • 8. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
    Huang MY, Chen MJ, Tsai HL, Kuo CH, Ma CJ, Hou MF, Chuang SC, Lin SR, Wang JY.
    Genet Mol Res; 2011 Oct 03; 10(4):3002-12. PubMed ID: 21968808
    [Abstract] [Full Text] [Related]

  • 9. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.
    Ciardiello F, Normanno N, Maiello E, Martinelli E, Troiani T, Pisconti S, Giuliani F, Barone C, Cartenì G, Rachiglio AM, Montesarchio V, Tonini G, Rizzi D, Cinieri S, Bordonaro R, Febbraro A, De Vita F, Orditura M, Fenizia F, Lambiase M, Rinaldi A, Tatangelo F, Botti G, Colucci G.
    Ann Oncol; 2014 Sep 03; 25(9):1756-1761. PubMed ID: 24942275
    [Abstract] [Full Text] [Related]

  • 10. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.
    Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W, Zielinski CC.
    World J Gastroenterol; 2010 Jul 07; 16(25):3133-43. PubMed ID: 20593498
    [Abstract] [Full Text] [Related]

  • 11. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
    Kang MJ, Hong YS, Kim KP, Kim SY, Baek JY, Ryu MH, Lee JL, Chang HM, Kim MJ, Chang HJ, Kang YK, Kim TW.
    Invest New Drugs; 2012 Aug 07; 30(4):1607-13. PubMed ID: 21706149
    [Abstract] [Full Text] [Related]

  • 12. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
    Soeda H, Shimodaira H, Watanabe M, Suzuki T, Gamoh M, Mori T, Komine K, Iwama N, Kato S, Ishioka C.
    Int J Clin Oncol; 2013 Aug 07; 18(4):670-7. PubMed ID: 22638623
    [Abstract] [Full Text] [Related]

  • 13. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
    Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P.
    Ann Oncol; 2011 Jul 07; 22(7):1535-1546. PubMed ID: 21228335
    [Abstract] [Full Text] [Related]

  • 14. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
    Fornaro L, Lonardi S, Masi G, Loupakis F, Bergamo F, Salvatore L, Cremolini C, Schirripa M, Vivaldi C, Aprile G, Zaniboni A, Bracarda S, Fontanini G, Sensi E, Lupi C, Morvillo M, Zagonel V, Falcone A.
    Ann Oncol; 2013 Aug 07; 24(8):2062-7. PubMed ID: 23666916
    [Abstract] [Full Text] [Related]

  • 15. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
    Lee JJ, Chu E.
    Clin Colorectal Cancer; 2014 Sep 07; 13(3):135-44. PubMed ID: 24768040
    [Abstract] [Full Text] [Related]

  • 16. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.
    Hong YS, Kim HJ, Park SJ, Kim KP, Lee JL, Park JH, Kim JH, Lim SB, Yu CS, Kim JC, Baek JY, Kim SY, Kim TW.
    Cancer Sci; 2013 Apr 07; 104(4):473-80. PubMed ID: 23298313
    [Abstract] [Full Text] [Related]

  • 17. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
    Colucci G, Giuliani F, Garufi C, Mattioli R, Manzione L, Russo A, Lopez M, Parrella P, Tommasi S, Copetti M, Daniele B, Pisconti S, Tuveri G, Silvestris N, Maiello E.
    Oncology; 2010 Apr 07; 79(5-6):415-22. PubMed ID: 21474966
    [Abstract] [Full Text] [Related]

  • 18. No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis.
    Zhou SW, Huang YY, Wei Y, Jiang ZM, Zhang YD, Yang Q, Xie DR.
    PLoS One; 2012 Apr 07; 7(11):e50925. PubMed ID: 23226426
    [Abstract] [Full Text] [Related]

  • 19. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
    Van Cutsem E, Lenz HJ, Köhne CH, Heinemann V, Tejpar S, Melezínek I, Beier F, Stroh C, Rougier P, van Krieken JH, Ciardiello F.
    J Clin Oncol; 2015 Mar 01; 33(7):692-700. PubMed ID: 25605843
    [Abstract] [Full Text] [Related]

  • 20. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
    Soeda H, Shimodaira H, Gamoh M, Ando H, Isobe H, Suto T, Takahashi S, Kakudo Y, Amagai K, Mori T, Watanabe M, Yamaguchi T, Kato S, Ishioka C.
    Oncology; 2014 Mar 01; 87(1):7-20. PubMed ID: 24968756
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.